weight management options

GLP-1

GLP-1 agonists for weight loss

The FDA currently approves the use of GLP-1 agonists to help treat obesity. This is because these GLP-1 agonists have weight loss effects. Obesity is a chronic condition in which you have a body mass index (BMI) of 30 or higher.

Healthcare providers may also prescribe GLP-1’s for people who are overweight along with other health conditions if losing weight can help manage the coexisting conditions. Overweight is a BMI of 25 to 29.9

***Compounded medications 

Are NOT FDA-approved and are prescribed off-label based on individual medical need. Retatrutide is still in clinical trials.  We utilize compounding pharmacies from the Green List. Our Retatrutide is a research peptide.

Injections weekly in office

·

Compounded Tirzepatide

·

Research Peptide Retatrutide

·

Injections weekly in office · Compounded Tirzepatide · Research Peptide Retatrutide ·

Risks / Benefits

What are the potential benefits of GLP-1 agonists?

Other than lowering blood sugar levels and reducing weight, studies show that GLP-1 agonists may have other potential benefits, like:

What are the side effects of GLP-1 agonists?

The most common side effects of GLP-1 agonists include:

These side effects are more likely to happen when you start the medication or if you’re taking an increased dose.

Other side effects can include:

You may also have temporary mild itchiness and/or redness on your skin at the site of the injections.

Severe — but rare —

side effects can include:

Tirzepatide is a once-weekly injectable prescription medication that mimics two natural gut hormones (GIP and GLP-1) to improve blood sugar control and reduce appetite.

How It Works

  • Insulin regulation: Tells the pancreas to release more insulin when blood sugar levels are high.

  • Digestion slowdown: Delays how fast food leaves the stomach to help you feel full longer.

  • Appetite suppression: Acts on brain regions that control hunger and reduce food cravings.

    Side Effects & Risks

    • Mild to moderate: Nausea, vomiting, diarrhea, constipation, stomach pain, and decreased appetite.

    • Serious warnings: Risk of thyroid C-cell tumors (seen in animal studies); do not use if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

    • Other risks: Pancreatitis, gallbladder problems, or severe low blood sugar when combined with other diabetes drugs like insulin.

BOOK AN APPOINTMENT

Retatrutide is an investigational triple-hormone receptor agonist. It activates GLP-1, GIP, and glucagon receptors, helping control appetite, lower blood sugar, and increase energy expenditure. Clinical trials show substantial weight loss, but the drug is not yet FDA-approved.

How Retatrutide Works

  • GLP-1 (Glucagon-like peptide-1): Slows digestion and increases feelings of fullness.

  • GIP (Glucose-dependent insulinotropic polypeptide): Works with GLP-1 to manage blood sugar and reduce hunger.

  • Glucagon: Increases resting energy expenditure and promotes the burning of liver fat.

    Clinical Trial Results

    • Weight Loss: Phase 3 clinical trials demonstrated that participants taking the highest dose (12 mg) lost an average of about 28% of their starting body weight over 80 weeks.

    • Studies are tracking improvements in knee osteoarthritis pain, type 2 diabetes management, and cardiovascular risk factors.

      Side Effects and Risks

      • Common Effects: Similar to other

        GLP-1medications, users commonly experience nausea, vomiting, and constipation. Some trial participants reported unique skin sensations (allodynia/hyperesthesia).